BACKGROUND: Uremic syndrome is the consequence of the retention of solutes usually cleared by the healthy kidneys. p-Cresol can be considered a prototypic protein-bound uremic toxin. It is conceivable, analogous with drugs, that the non-protein-bound fraction of p-cresol exerts toxicity. This aspect had never been evaluated, nor have the factors influencing the free fraction of p-cresol. METHODS: In a transsectional study we evaluated the relationship between prehemodialysis free p-cresol and the ratio of free to total p-cresol (F:T) to clinical and biological factors in 44 chronic renal failure patients. The evolution of free p-cresol was assessed prospectively in 12 patients showing a change in serum albumin of at least 5 g/L over time. Hospitalization days attributable to infection and the free p-cresol concentrations were noted over a 1-year period. The impact of free p-cresol in vitro on leukocyte functional capacity was evaluated by chemiluminescence. RESULTS: We observed a correlation between total and free p-cresol (r = 0.84; P <0.001). In the multivariate analyses, free p-cresol and F:T showed a negative correlation with albumin. A shift from normal serum albumin to hypoalbumininemia in 12 patients led to an increase in free p-cresol from 5.9 +/- 3.2 to 8.2 +/- 4.5 micro mol/L (P <0.05; 0.64 +/- 0.35 to 0.89 +/- 0.49 mg/L). Free p-cresol (P <0.05) was higher in the patients hospitalized for infectious disease. In vitro, free p-cresol was higher in a 25 g/L than in a 50 g/L albumin solution (P <0.05). Leukocyte chemiluminescence production was more inhibited in the low albumin (high free p-cresol) solution (28% +/- 6% vs 21% +/- 8%; P <0.05). CONCLUSIONS: Hypoalbuminemia and total p-cresol increase the free fraction of p-cresol. Patients hospitalized for infections have higher free p-cresol. In vitro, high free p-cresol has a negative impact on leukocyte chemiluminescence production. These data demonstrate the toxicity of free p-cresol.
BACKGROUND:Uremic syndrome is the consequence of the retention of solutes usually cleared by the healthy kidneys. p-Cresol can be considered a prototypic protein-bound uremic toxin. It is conceivable, analogous with drugs, that the non-protein-bound fraction of p-cresol exerts toxicity. This aspect had never been evaluated, nor have the factors influencing the free fraction of p-cresol. METHODS: In a transsectional study we evaluated the relationship between prehemodialysis free p-cresol and the ratio of free to total p-cresol (F:T) to clinical and biological factors in 44 chronic renal failurepatients. The evolution of free p-cresol was assessed prospectively in 12 patients showing a change in serum albumin of at least 5 g/L over time. Hospitalization days attributable to infection and the free p-cresol concentrations were noted over a 1-year period. The impact of free p-cresol in vitro on leukocyte functional capacity was evaluated by chemiluminescence. RESULTS: We observed a correlation between total and free p-cresol (r = 0.84; P <0.001). In the multivariate analyses, free p-cresol and F:T showed a negative correlation with albumin. A shift from normal serum albumin to hypoalbumininemia in 12 patients led to an increase in free p-cresol from 5.9 +/- 3.2 to 8.2 +/- 4.5 micro mol/L (P <0.05; 0.64 +/- 0.35 to 0.89 +/- 0.49 mg/L). Free p-cresol (P <0.05) was higher in the patients hospitalized for infectious disease. In vitro, free p-cresol was higher in a 25 g/L than in a 50 g/L albumin solution (P <0.05). Leukocyte chemiluminescence production was more inhibited in the low albumin (high free p-cresol) solution (28% +/- 6% vs 21% +/- 8%; P <0.05). CONCLUSIONS:Hypoalbuminemia and total p-cresol increase the free fraction of p-cresol. Patients hospitalized for infections have higher free p-cresol. In vitro, high free p-cresol has a negative impact on leukocyte chemiluminescence production. These data demonstrate the toxicity of free p-cresol.
Authors: Anneleen Pletinck; Griet Glorieux; Eva Schepers; Gerald Cohen; Bertrand Gondouin; Maria Van Landschoot; Sunny Eloot; Angelique Rops; Johan Van de Voorde; An De Vriese; Johan van der Vlag; Philippe Brunet; Wim Van Biesen; Raymond Vanholder Journal: J Am Soc Nephrol Date: 2013-09-05 Impact factor: 10.121
Authors: Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux Journal: J Am Soc Nephrol Date: 2014-05-08 Impact factor: 10.121
Authors: Nathaniel Berman; Melisa Lectura; Josh Thurman; James Reinecke; Amanda C Raff; Michal L Melamed; James Reinecke; Zhe Quan; Todd Evans; Timothy W Meyer; Thomas H Hostetter Journal: Blood Purif Date: 2013-05-08 Impact factor: 2.614
Authors: Christos Argyropoulos; Chung-Chou H Chang; Laura Plantinga; Nancy Fink; Neil Powe; Mark Unruh Journal: J Am Soc Nephrol Date: 2009-07-30 Impact factor: 10.121
Authors: Sophie Liabeuf; Griet Glorieux; Aurelie Lenglet; Momar Diouf; Eva Schepers; Lucie Desjardins; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: A Noce; M Ferrannini; R Fabrini; A Bocedi; M Dessì; F Galli; G Federici; R Palumbo; N Di Daniele; G Ricci Journal: Cell Death Dis Date: 2012-08-23 Impact factor: 8.469